Pemphigus Vulgaris - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Pemphigus Vulgaris - Pipeline Review, H2 2018’, provides an overview of the Pemphigus Vulgaris pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris

- The report reviews pipeline therapeutics for Pemphigus Vulgaris by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Pemphigus Vulgaris therapeutics and enlists all their major and minor projects

- The report assesses Pemphigus Vulgaris therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Pemphigus Vulgaris

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Pemphigus Vulgaris pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Argenx SE

Biogen Inc

HanAll Biopharma Co Ltd

Immunomedics Inc

Novartis AG

Principia Biopharma Inc

Rubius Therapeutics Inc

Syntimmune Inc

Argenx SE

Biogen Inc

HanAll Biopharma Co Ltd

Immunomedics Inc

Novartis AG

Principia Biopharma Inc

Rubius Therapeutics Inc

Syntimmune Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pemphigus Vulgaris - Overview

Pemphigus Vulgaris - Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pemphigus Vulgaris - Overview

Pemphigus Vulgaris - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pemphigus Vulgaris - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pemphigus Vulgaris - Companies Involved in Therapeutics Development

Argenx SE

Biogen Inc

HanAll Biopharma Co Ltd

Immunomedics Inc

Novartis AG

Principia Biopharma Inc

Rubius Therapeutics Inc

Syntimmune Inc

Pemphigus Vulgaris - Drug Profiles

Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPC-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

efgartigimod alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Pemphigus Vulgaris - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HL-161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ianalumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

orilanolimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRN-1008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RTX-PV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veltuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pemphigus Vulgaris - Dormant Projects

Pemphigus Vulgaris - Discontinued Products

Pemphigus Vulgaris - Product Development Milestones

Featured News & Press Releases

Jul 24, 2018: argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation

Jun 20, 2018: argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris

Jun 14, 2018: argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation

Jun 07, 2018: FDA Approves Genentech's Rituxan (rituximab) For Pemphigus Vulgaris

Feb 13, 2018: FDA Grants Priority Review for Genentech’s Rituxan (Rituximab) for Pemphigus Vulgaris

Dec 11, 2017: argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

Nov 02, 2017: Argenx to Host KOL Breakfast Symposium on Pemphigus Vulgaris

Oct 30, 2017: Argenx Launches Phase I Trial with Subcutaneous Formulation of ARGX-113

Sep 26, 2017: argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris

Sep 18, 2017: Principia Biopharma Presents Late-Breaking Interim Phase 2 Data of PRN1008 in Pemphigus at European Academy of Dermatology and Venereology Meeting

Jul 11, 2017: Principia Biopharma Announces PRN1008 Receives Orphan Drug Designation From FDA for Treatment of Pemphigus Vulgaris

Mar 24, 2017: FDA grants breakthrough therapy designation for MabThera/Rituxan (rituximab) in pemphigus vulgaris

Jan 07, 2016: Principia Biopharma Advances BTK Inhibitor Program in Autoimmune Disease and FGFR Inhibitor Program in Oncology

Aug 25, 2015: Genentech Initiates Phase III Trial of Rituxan for Rare, Autoimmune Disease: Pemphigus Vulgaris

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Pemphigus Vulgaris, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Pemphigus Vulgaris, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pemphigus Vulgaris - Pipeline by Argenx SE, H2 2018

Pemphigus Vulgaris - Pipeline by Biogen Inc, H2 2018

Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co Ltd, H2 2018

Pemphigus Vulgaris - Pipeline by Immunomedics Inc, H2 2018

Pemphigus Vulgaris - Pipeline by Novartis AG, H2 2018

Pemphigus Vulgaris - Pipeline by Principia Biopharma Inc, H2 2018

Pemphigus Vulgaris - Pipeline by Rubius Therapeutics Inc, H2 2018

Pemphigus Vulgaris - Pipeline by Syntimmune Inc, H2 2018

Pemphigus Vulgaris - Dormant Projects, H2 2018

Pemphigus Vulgaris - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Pemphigus Vulgaris, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Pemphigus Vulgaris, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports